[
  {
    "ts": null,
    "headline": "Danaher Corp. stock outperforms competitors despite losses on the day",
    "summary": "Danaher Corp. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=b443f71fe51694ea125850829d56724269709640dbc2c9a109a62872b1e17b6d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754498160,
      "headline": "Danaher Corp. stock outperforms competitors despite losses on the day",
      "id": 136252471,
      "image": "",
      "related": "DHR",
      "source": "MarketWatch",
      "summary": "Danaher Corp. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=b443f71fe51694ea125850829d56724269709640dbc2c9a109a62872b1e17b6d"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne beats quarterly estimates on strength in protein sciences unit",
    "summary": "Bio-Techne reported better-than-expected fourth-quarter revenue and profit on Wednesday, helped by steady demand for its proteins, antibodies and other products for research. The Minneapolis, Minnesota-based company develops and makes products used in medical research, drug development and diagnostics. Larger peers Thermo Fisher and Danaher last month flagged robust demand across regions for their drug development products such as instruments and analytical tools after two years of weak biotech funding.",
    "url": "https://finnhub.io/api/news?id=d9b9ffb22d280130ac28c287d3bd45c0d6eadb9459e304254a41596bd825710c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754482090,
      "headline": "Bio-Techne beats quarterly estimates on strength in protein sciences unit",
      "id": 136237313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Bio-Techne reported better-than-expected fourth-quarter revenue and profit on Wednesday, helped by steady demand for its proteins, antibodies and other products for research. The Minneapolis, Minnesota-based company develops and makes products used in medical research, drug development and diagnostics. Larger peers Thermo Fisher and Danaher last month flagged robust demand across regions for their drug development products such as instruments and analytical tools after two years of weak biotech funding.",
      "url": "https://finnhub.io/api/news?id=d9b9ffb22d280130ac28c287d3bd45c0d6eadb9459e304254a41596bd825710c"
    }
  },
  {
    "ts": null,
    "headline": "Charles River raises profit forecast on growing demand for drug development services",
    "summary": "The Wilmington, Massachusetts-based contract drug developer raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, compared with its previous projection of $9.30 to $9.80.  Contract research organizations, which reported quarterly results over the last month, have all posted better-than-expected profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing.  \"We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth,\" Charles River CEO James Foster said.",
    "url": "https://finnhub.io/api/news?id=fbe317e351add6183ffacd589fd19e54aee1d6bec690e710aa90af19b7102de2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481342,
      "headline": "Charles River raises profit forecast on growing demand for drug development services",
      "id": 136232400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "The Wilmington, Massachusetts-based contract drug developer raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, compared with its previous projection of $9.30 to $9.80.  Contract research organizations, which reported quarterly results over the last month, have all posted better-than-expected profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing.  \"We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth,\" Charles River CEO James Foster said.",
      "url": "https://finnhub.io/api/news?id=fbe317e351add6183ffacd589fd19e54aee1d6bec690e710aa90af19b7102de2"
    }
  }
]